Related Experiment Video

Updated: Jul 9, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Association of polymorphisms in platelet and hemostasis system genes with acute myocardial infarction

Joshua W Knowles1, Huijan Wang, Haruka Itakura

  • 1Stanford University School of Medicine, Stanford, CA 94305-5405, USA.

American Heart Journal
|November 24, 2007
PubMed

Insights

Genetic variations in coagulation genes may influence acute myocardial infarction (MI) risk. Specific single nucleotide polymorphisms (SNPs) in CD36, ITGB3, and THBD showed associations with MI in coronary artery disease patients.

Area of Science:

  • Cardiovascular Genetics
  • Hemostasis and Thrombosis

Background:

  • Genetic polymorphisms can disrupt the coagulation-fibrinolysis balance.
  • This imbalance may increase susceptibility to acute myocardial infarction (MI) in individuals with coronary atherosclerosis.

Purpose of the Study:

  • To investigate the association between genetic polymorphisms in coagulation system genes and the risk of acute myocardial infarction (MI).
  • To compare the frequency of specific single nucleotide polymorphisms (SNPs) between patients presenting with acute MI and those with stable exertional angina.

Main Methods:

  • Genotyped 49 single nucleotide polymorphisms (SNPs) in 9 coagulation system genes.
  • Enrolled 1375 patients with coronary disease, comparing those with acute MI to those with stable exertional angina.

Main Results:

  • An SNP in CD36 (rs3211956) was more common in acute MI patients (10.5%) vs. stable angina (8.0%), P=.04.
  • Associations for SNPs in ITGB3 and THBD were not statistically significant but showed trends.
  • The CD36 association became marginally significant after adjusting for cardiac risk factors (OR 1.34, P=.053).

Conclusions:

  • Nominal associations were found between four SNPs in platelet glycoprotein and hemostatic genes and acute MI presentation.
  • These findings suggest a potential role for these genetic variations but require validation in larger cohorts.
Abstract

More Related Videos

Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease08:51

Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease

Published on: September 20, 2024

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...